Table 1 Overview of past and current investigations by RNAi in HIV therapy
From: Editing out HIV: application of gene editing technology to achieve functional cure
Years | Target | Cell types/organisms | References |
|---|---|---|---|
2015 | CCR5 and six regions in the viral genome | Hu-PBL mouse model | Choi et al. [96] |
2018 | The 5′ long terminal repeat (LTR) | Infected T lymphoblastoid CEM cell line and primary human CD4+ T-cells | Zhou et al. [23] |
2019 | HIV-1 Tat subtypes | HEK293T cells and TZM-bl cells | Ronsard et al. [97] |
2019 | HIV-1-enhanced lncRNA (HEAL) | MT4 and H9 cells and E4 Jurkat cells | Chao et al. [20] |
2020 | EC-LTNP or LTNP | Peripheral blood mononuclear cells (PBMCs) | Ayala-Suarez et al. [98] |
2020 | Long terminal repeat indexing-mediated integration site sequencing (LTRi-Seq) | Human CD34+ HSPCs and human fetal thymus and fetal livers | Suryawanshi et al. [27] |
2020 | NOP2 | HIV-infected T cell line J89GFP and THP89GFP HIV-1 latency cell lines CD4+ T cells MAGI-HeLa, TZM-bl, and HEK293T fembryonic kidney cells | Kong et al. [99] |